The researchers presented safety results in an accompanying poster and reported a 65% (P less than 0.001) reduction in the rate of clinically significant exacerbations for patients with SAE who switched to mepolizumab. They also reported a 69% (P less than 0.001) reduction in exacerbations that required ED visits and/or hospitalizations.
“This study provides practical reassurance to clinicians considering substituting one biologic for another in the treatment of patients with SEA,” the researchers concluded.
This research was funded by GlaxoSmithKline, the makers of mepolizumab.
chestphysiciannews@chestnet.org
SOURCE: Albers FC et al. AAAAI/WAO Joint Congress, Posters L29 and L30.
http://www.jacionline.org/article/S0091-6749(17)32864-6/abstract